Warf-backed 4490 Ventures has returned to supply funding to weather analytics service Understory in support of the latter’s international expansion and recruitment strategy.

The immunotherapy developer, which is exploits Yale University research and counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.

The Posco-backed pulmonary device maker has collected $65m in an oversubscribed round led by Ally Bridge Group, taking its equity funding to $135m to date.

The immunotherapy developer, which counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

Lundbeck-backed pruritus therapy developer Trevi Therapeutics raised $55m when it floated, but had to price its shares significantly below its range.

Hanwha Asset Management contributed to a round that boosted the online life insurance provider's overall funding to about $140m.

Mansi Parikh has left her director of global business and corporate development position at Verifone after nearly five years to manage strategic venture investments for Wells Fargo.

GumGum's dental tools spinoff has raised $11m from Craft Ventures and undisclosed strategic dental industry partners.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.